U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07390253) titled 'The Eylea 8mg Switch Study' on Jan. 28.
Brief Summary: This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual acuity.
Study Start Date: Sept. 18, 2024
Study Type: OBSERVATIONAL
Condition:
Neovascular (Wet) Age-Related Macular Degeneration
Intervention:
DRUG: Aflibercept
Intravitreal injection with high dose (8 mg) aflibercept
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Vienna Institute for Research in Ocular Surgery
Information provided by (Responsib...